Whalesbook
Chalo ab detail mein baat karte hain. Granules India, America ki FDA (Food and Drug Administration) se thoda pressure mein hai. Unke kuch important manufacturing sites par record-keeping aur contamination control ko lekar issues mile hain. Isko theek karne ke liye company ne apna focus operational upgrades aur digitization par badhaya hai, jaise ki 'gemba walks' aur digital logs. Ye sab zaroori hai kyunki company U.S. market par bahut depend karti hai, jahan regulations follow karna sabse important hai. Is upgrades mein lagat bohot aayegi aur quality control bhi sakht karna padega.
Stock ki baat karein toh, Granules India ka share abhi ₹644 ke aas paas trade kar raha hai, jo uske 52-week high ₹650 ke kaafi paas hai. Company ki market cap lagbhag ₹155 billion hai. Lekin, FDA ke warning letters aur Telangana facility ke VAI classification ki wajah se automation, data integrity aur control systems mein bada investment karna pad raha hai. Ye sab zaroori upgrades company ke profit margins par pressure daal sakte hain, jo investors ke liye ek chinta ka vishay ho sakta hai.
Granules India paracetamol aur API market mein ek bada player hai. Ab India mein pharma industry mein reforms aa rahe hain, jaise ki Schedule M norms jo January 1, 2026 se lagu honge, jismein quality aur data integrity par zyada zor diya jayega. Granules ke mamle mein, unke record-keeping aur contamination control ke specific FDA citations unki operational weaknesses ko highlight karte hain. U.S. mein unke packaging site ko 'No Action Indicated' (NAI) report mili thi March 2026 mein, par manufacturing plant abhi bhi VAI status mein hai, matlab issues hain. Analysts abhi bhi generally positive hain, unhone 'Buy' rating de rakhi hai aur price targets ₹623 se ₹682 ke beech hain. Lekin, Granules ka P/E ratio 28-29 ke aas paas hai, jo Aarti Drugs (15.9x) aur Dr. Reddy's Laboratories (17.9x) jaise competitors se zyada hai. Iska matlab hai ki investors ne company ko valuation mein premium diya hai, jise ye compliance kharche challenge kar sakte hain.
Purane issues ko bhulna mushkil hai. Company ke stock mein February 2025 mein warning letter ke baad lagbhag 8% aur September 2024 mein Gagillapur facility ke issues ke baad 16% se zyada ki girawat dekhi gayi thi. Ye volatility dikhati hai ki regulatory events kitne bade risk hain. Competitors ke compare mein jinke records saaf hain, Granules ko consistent compliance dikhane mein challenge face karna pad raha hai. U.S. market par unka zabardast reliance in risks ko aur badhata hai. Schedule M jaise regulations ke tehet advanced manufacturing aur quality controls mein continuous investment karne se margins kam ho sakte hain, jo unke liye ek traditionally cost-efficient API producer hone ke hisab se problematic hai. Ek executive director ne pehle ye bhi mana tha ki automation aur controls ko neglect kiya gaya tha, jo cautious investors ke liye worrying ho sakta hai.
Abhi bhi, bahut se analysts future ko lekar optimistic hain. Company ki growth ke liye kai factors hain: complex generics, oncology offerings, aur peptide CDMO services mein expansion. Regulatory issues solve hone ki bhi ummeed hai. Analysts ka anuman hai ki 2027 tak revenue mein 20% ka growth aur EPS mein 33% ka rise ho sakta hai. Unka robust R&D pipeline jismein 94 approvals hain, aur North America aur Europe mein finished dosage ka momentum bhi outlook ko support karta hai. Senn Chemicals AG ka integration aur healthy net debt to EBITDA ratio bhi company ke financial foundation ko stable banata hai.